|
Phase 3 randomized study of adjuvant anastrozole (A), exemestane (E), or letrozole (L) with or without tamoxifen (T) in postmenopausal women with hormone-responsive (HR) breast cancer: The FATA-GIM3 trial. |
|
|
Honoraria - Amgen; Bayer; Bayer; Bayer; Daiichi Sankyo; Lilly; Novartis; Roche |
Research Funding - Bayer (Inst); Roche (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Lilly; Roche; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Novartis; Pfizer |
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; GlaxoSmithKline; Roche; Takeda |
Consulting or Advisory Role - Amgen; Celgene; Eisai; GlaxoSmithKline; Roche; Takeda |
Research Funding - Eisai (Inst) |
Expert Testimony - Celgene |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Roche; Takeda |
Consulting or Advisory Role - Lilly; Novartis; Pfizer |
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Merck |
Travel, Accommodations, Expenses - Celgene; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Speakers' Bureau - AstraZeneca; Novartis; Roche |
|
|
Honoraria - GlaxoSmithKline; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - AstraZeneca (Inst) |